Endonovo Therapeutics Inc

General ticker "ENDV" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $262.8K

Endonovo Therapeutics Inc does not follow the US Stock Market performance with the rate: -43.6%.

Estimated limits based on current volatility of 21.8%: low 0.00$, high 0.00$

Factors to consider:

  • Current price 88.5% below estimated low
  • Earnings for 6 months up through Q2 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [0.00$, 0.02$]
  • 2024-12-30 to 2025-12-30 estimated range: [0.00$, 0.02$]

Financial Metrics affecting the ENDV estimates:

  • Negative: Non-GAAP EPS, $ of -0.01 <= 0.10
  • Negative: Operating profit margin, % of -95.42 <= 1.03
  • Positive: Return on assets ratio (scaled to [-100,100]) of 91.54 > 7.10
  • Positive: 2.35 < Operating cash flow per share per price, % of 4.58
  • Positive: Industry inventory ratio change (median), % of 0 <= 0

Similar symbols

Short-term ENDV quotes

Long-term ENDV plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.07MM $0.14MM $0.14MM
Operating Expenses $2.30MM $3.40MM $3.06MM
Operating Income $-2.23MM $-3.26MM $-2.92MM
Non-Operating Income $-0.88MM $-15.21MM $9.84MM
Interest Expense $0.94MM $1.32MM $1.28MM
Income(Loss) $-3.10MM $-18.47MM $6.92MM
Profit(Loss) $-3.10MM $-18.47MM $6.92MM
Stockholders Equity $-15.77MM $-32.18MM $-24.11MM
Assets $2.01MM $1.28MM $0.64MM
Operating Cash Flow $-0.99MM $-0.68MM $0.12MM
Financing Cash Flow $1.06MM $0.59MM $-0.12MM
Earnings Per Share* $-0.07 $-0.23 $0.03

* EPS are Split Adjusted, recent splits may be reflected with a delay.